


SAPIEN 3 Ultra RESILIA system

Designed for Lifetime
Management Strategy



The SAPIEN 3 Ultra RESILIA valve benefits are mainly driven by lower rates of complications and PVL⁷



Building on the performance of the SAPIEN 3 Ultra valve, SAPIEN 3 Ultra RESILIA valve offers lower gradient, consistent across all valve sizes


CI, confidence interval; HR, hazard ratio; LT, life threatening; MVC, major vascular complication; PVL, paravalvular leak; S3, SAPIEN 3 valve; S3U, SAPIEN 3 Ultra valve; S3UR, SAPIEN 3 Ultra RESILIA valve.

Permanent pacemaker and stroke with SAPIEN 3 Ultra RESILIA valve at 30 days¹⁰



Consistently excellent 1-year clinical outcomes⁷


Significantly lower echo-derived mean gradients and larger EOAs across all valve sizes



* Compared to SAPIEN 3 and SAPIEN 3 Ultra valves | EOA, effective orifice area

SAPIEN 3 Ultra RESILIA valve - designed for Lifetime management

Built on the legacy of SAPIEN 3 Ultra valve and INSPIRIS RESILIA valve



SAPIEN 3 Ultra RESILIA valve delivers excellent performance⁷


Equally excellent outcomes when compared with SAPIEN 3/SAPIEN 3 Ultra valves

1-year clinical outcomes (propensity matched)	All-cause mortality	Stroke	Life-threatening bleeding	Permanent pacemaker implantation	AKI Stage 4	Aortic valve reintervention
 SAPIEN 3 / SAPIEN 3 Ultra THV (n=4,598)	9.7% (356)	3.2% (130)	2.7% (110)	9.6% (384)	0.6% (23)	0.4% (16)
 SAPIEN 3 Ultra RESILIA THV (n=4,598)	7.6% (261)	2.7% (108)	2.0% (78)	10.6% (419)	0.6% (25)	0.6% (22)


Most implanted Transcatheter Heart Valve in United States

THV, transcatheter heart valve.

RESILIA tissue technology to mitigate leaflets calcification⁸




Eight-years clinical data from a surgical propensity-score matching confirms RESILIA tissue technology's excellent long-term performance⁹




* Standardized definition of SVD was utilized (Akins et. al 2008)

?How do we enable future procedures and coronary access



100% Coronary access⁶
thanks to:

- Low frame design
- Open cell geometry



THV-in-SAV*

Aortic THV-in-THV*

The only one approved for
Aortic THV-in-THV



THV-in-Surgical Mitral valve*

The only one approved for
THV-in-Surgical Mitral valve

Approved for both THV in SAVR and THV in THV

THV, transcatheter heart valve; SAV, surgical aortic valve; SAVR, surgical aortic valve replacement.

RESILIA tissue technology – Results from economic analyses based on assumptions informed by surgical data

Reintervention reduction may result in significant savings at 8 years

Incidence of
reoperation due to
SVD[†] at 8 years**

0.8%

RESILIA tissue
(COMMENCE trial n=689)

6.1%

Non-RESILIA tissue
(Magna Ease n=258)



Country	Potential reintervention cost* TAVI Low risk	Potential reintervention cost with RESILIA per patient	Potential reinter- vention cost with non-RESILIA per patient	Potential cost savings with RESILIA valves per patient (Δ)
Norway	NOK 378 148 ¹¹	NOK 3 025	NOK 23 067	NOK 20 042
France	€ 26 130 ¹²	€ 209	€ 1 594	€ 1 385
Italy	€ 36 945 ¹³	€ 296	€ 2 254	€ 1 958
Spain	€ 30 058 ¹⁴	€ 240	€ 1 834	€ 1 593
Germany	€ 30 051 ¹⁵	€ 240	€ 1 833	€ 1 593
Belgium	€ 32 962 ¹⁶	€ 264	€ 2 011	€ 1 747
Netherlands	€ 43 163 ¹⁷	€ 345	€ 2 633	€ 2 288
Switzerland	CHF 52 953 ¹⁸	CHF 424	CHF 3 230	CHF 2 807
Sweden	SEK 337 188 ¹⁹	SEK 2 698	SEK 20 568	SEK 17 871
UK	£ 33 084 ²⁰	£ 265	£ 2 018	£ 1 753

[†]Standardized definition of SVD was utilized (Akins et. al 2008)

*Costs were based on cost information from published literature, and adjusted for inflation to 2024 when necessary unless otherwise stated.

** Financial savings were calculated based on Kaneko et al. (presented at HVS 2025).

Assumptions: As no additional risk of reintervention with SAPIEN 3 vs. SAVR from PARTNER 2 SAPIEN 3i²¹ and PARTNER 3²² was observed using same VARC 3 definitions of BVD and SVD at 5 years, SAPIEN 3 Ultra RESILIA valve is expected to have similar durability to SAVR.

References:

1. Data on file
2. De la Fuente et al. Advanced Integrity Preservation Technology Reduces Bioprosthesis Calcification While Preserving Performance and Safety. *Journal of Heart Valve Disease*. 2015.
3. Data on file
4. Kodali S et al. Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards SAPIEN valve in the PARTNER trial: characterizing patients and impact on outcomes. *Eur Heart J*. 2015
5. Makkar R et al. Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement. *N Engl J Med*. 2020
6. Tarantini et al. Coronary Access After Transcatheter Aortic Valve Replacement With Commissural Alignment: The ALIGN-ACCESS Study - *Circ Cardiovasc Interv* 2022 Feb;15(2):e011045. Epub 2022 Feb 15.
7. Kini AS et al. *JACC Cardiovasc Interv*. 2024; doi: 10.1016/j.jcin.2024.11.015
8. De la Fuente AB, Wright GA, Olin JM, et al. Advanced Integrity Preservation Technology Reduces Bioprosthesis Calcification While Preserving Performance and Safety. *Journal of Heart Valve Disease*. 2015.
9. Kaneko, T, Johnston D, Bavaria JE, et al. Propensity-matched 8-year Outcomes Following Surgical Aortic Valve Replacement with ith Novel Calcification-resistant Versus Contemporary Tissue Bioprostheses. Presented at the Heart Valve Society Annual Scientific Meeting, April 2025.
10. Stinis CT et al. *JACC Cardiovasc Interv*. 2024; 17: 1032–44
11. Norwegian Institute of Public Health (NIPH). Transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR) for patients with severe aortic stenosis and low surgical risk and across surgical risk groups: a health technology assessment 2021 [Available from: <https://www.fhi.no/en/publ/2021/TAVI-vs-SAVR-for-patients-with-severe-aortic-stenosis-and-low-surgical-risk-and-across-surgical-risk-groups/>].
12. Gilard M, Eltchaninoff H, Iung B, et al. Cost-effectiveness analysis of SAPIEN 3 TAVI procedure compared with surgery in patients with severe aortic stenosis at low risk of surgical mortality in France. *Value Health* 2022;25:605–13.
13. Mennini FS, Meucci F, Pesarini G, et al. Cost-effectiveness of transcatheter aortic valve implantation versus surgical aortic valve replacement in low surgical risk aortic stenosis patients. *Int J Cardiol* 2022;357:26–32.
14. Vázquez Rodríguez JM, Bermúdez EP, Zamorano JL, et al. Cost-effectiveness of SAPIEN 3 transcatheter aortic valve implantation in low surgical mortality risk patients in Spain. *REC Interv Cardiol* 2023:38–45.
15. Kuck KH, Leidl R, Frankenstein L, et al. Cost-Effectiveness of SAPIEN 3 Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in German Severe Aortic Stenosis Patients at Low Surgical Mortality Risk. *Adv Ther* 2023;40:1031–46.
16. Dubois C, Adriaenssens T, Annemans L, et al. Transcatheter aortic valve implantation versus surgical aortic valve replacement in severe aortic stenosis patients at low surgical mortality risk: a cost-effectiveness analysis in Belgium. *Acta Cardiol* 2024;79:46–57.
17. Eerdeken R, Kats S, Grutters JP, et al. Cost-utility analysis of TAVI compared with surgery in patients with severe aortic stenosis at low risk of surgical mortality in the Netherlands. *Cost Eff Resour Alloc* 2024;22:24.
18. Wyss CA, Corti R, Nestelberger T, et al. Transcatheter aortic valve implantation with SAPIEN 3 versus surgical aortic valve replacement in patients with symptomatic severe aortic stenosis at low risk of surgical mortality: a cost-utility analysis for Switzerland. *Swiss Med Wkly [Internet]* 2024;154:3558.
19. Nilsson K, James S, Angerås O, et al. Cost-effectiveness analysis of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis at low risk of surgical mortality in Sweden. *Upsala J Med Sci* 2024;129:e10741.
20. Candolfi P, McCarthy P, Blackman DJ T, Clinton TL, Aetesam-Ur-Rahman M, Bromilow T, Sellitto V, Curzen N. Cost-utility analysis of TAVI vs surgery in low-risk patients with severe aortic stenosis in the UK. *Open Heart* [submitted].
21. Madhavan MV, et al. Outcomes of SAPIEN 3 Transcatheter Aortic Valve Replacement Compared With Surgical Valve Replacement in Intermediate-Risk Patients. *J Am Coll Cardiol*. 2023.
22. Mack MJ, et al. PARTNER 3 Investigators. Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years. *N Engl J Med*. 2023.
23. Beaver T, Bavaria JE, Griffith B, et al. Seven year outcomes following aortic valve replacement with a novel tissue bioprosthesis. *J Thorac Cardiovasc Surg*. 2024 Sep;168(3):781-791.

Abbreviations:

CI, confidence interval
EOA, effective orifice area
HR, hazard ratio
LT, life threatening
MVC, major vascular complication
PPI, Permanent Pacemaker Implantation
PVL, paravalvular leak
SAV, surgical aortic valve
SAVR, surgical aortic valve replacement
S3, SAPIEN 3 valve
S3U, SAPIEN 3 Ultra valve
S3UR, SAPIEN 3 Ultra RESILIA valve.
THV, transcatheter heart valve

Clinical data on surgical valves with RESILIA tissue up to 7-year follow-up have been published, with additional follow-up to 10-years in progress.²³

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

Edwards, Edwards Lifesciences, the stylized E logo, Carpentier-Edwards, Carpentier-Edwards PERIMOUNT, COMMENCE, EDWARDS INTUITY, INSPIRIS RESILIA, Magna, Magna Ease, MITRIS RESILIA, PARTNER, PARTNER 3, PERI, PERIMOUNT, RESILIA, SAPIEN, SAPIEN 3, SAPIEN 3 Ultra and TheraFix are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2026 Edwards Lifesciences Corporation. All rights reserved. PP--EU-10644 v2.0

Edwards Lifesciences Sàrl • Route de l'Etraz 70, 1260 Nyon, Switzerland • edwards.com

